Home
Clinical Trials
NCT07187115

A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation

Last Updated: 2025-12-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

Total Enrollment

699 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-07

Study Completion Date

2030-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to establish the safety of the pulsed field ablation (PFA) therapy of Pulmonary Veins and Electrographic Flow (EGF) identified extra-PV sources of atrial fibrillation (PVI + EGF ablation of sources) and to demonstrate its non-inferiority in effectiveness compared to PFA of Pulmonary Veins and LA Posterior Wall (PVI+ PWA) in the treatment of de novo symptomatic drug-refractory persistent atrial fibrillation (PersAF).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation (AF) Persistant Atrial Fibrillation

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

FARAPULSE FARAPOINT OptiMap

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

plus non-randomized cohorts (Attempt, Roll-in)

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

The investigators and staffs will be blinded to the EGF maps in Control Arm.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Arm

PVI + PWA: The Control Arm, consisting of subjects undergoing PVI + PWA. PWA will be performed adjunctive to PVI per protocol Section 10.8.10. Following confirmation of PWA, EGF mapping will be performed in the LA and RA, while Investigators, lab/nursing staff, and research personnel are blinded to the EGF maps.

Group Type ACTIVE_COMPARATOR

OptiMap System (non-ablative)

Intervention Type DEVICE

An electrophysiology mapping system that uses a proprietary algorithm to analyze electrogram signals.

FARAPULSE Pulsed Field Ablation (PFA) System and Opal HDx Mapping System

Intervention Type DEVICE

All subjects will undergo electroanatomical mapping of the entire left atrium with the FARAWAVE NAV Catheter and Opal HDx Mapping System, followed by PFA PVI with the FARAWAVE NAV PFA Catheter, per the instructions of use.

Treatment Arm

PVI + EGF source(s) ablation: The Treatment Arm, consisting of subjects undergoing PVI + EGF source(s) ablation. Adjunctive to PVI, the EGF-identified active sources above threshold will be ablated per protocol Section 10.8.11. If following PVI, a narrow channel that is approximately ≤ 1 cm is identified in the LAPW, ablation may be performed using the FARAPOINT Catheter.

Group Type EXPERIMENTAL

FARAPOINT Pulsed Field Ablation System

Intervention Type DEVICE

A component of the FARAPULSE Pulsed Field Ablation (PFA) System and is a multi-electrode bidirectional, deflectable percutaneous catheter, an adjunctive catheter designed to create focal-type lesions for the creation of an ablation line between the inferior vena cava and the tricuspid valve.

OptiMap System (non-ablative)

Intervention Type DEVICE

An electrophysiology mapping system that uses a proprietary algorithm to analyze electrogram signals.

FARAPULSE Pulsed Field Ablation (PFA) System and Opal HDx Mapping System

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FARAPOINT Pulsed Field Ablation System

Intervention Type DEVICE

OptiMap System (non-ablative)

An electrophysiology mapping system that uses a proprietary algorithm to analyze electrogram signals.

Intervention Type DEVICE

FARAPULSE Pulsed Field Ablation (PFA) System and Opal HDx Mapping System

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ablamap System

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. ≥ 18 years of age, or older if required by local law
2. Have symptomatic drug-refractory1, persistent AF2, confirmed by both:

* Documentation, such as physician note, of persistent continuous AF for \> 7 days and ≤ 365 days and the arrhythmia symptoms
* Documentation, within 180 days of enrollment date of either:

* A 24-hour continuous ECG recording confirming continuous AF or
* Two (2) ECGs (from any regulatory cleared rhythm monitoring device) showing continuous AF taken at least 7 days apart
3. Willing and capable of providing informed consent
4. Willing and capable of participating in all follow-up assessments and testing associated with this clinical investigation at an approved clinical investigational center
5. Willing to receive LUX-Dx™ insertable cardiac monitor (ICM) during the study or already has a LUX-Dx™ ICM that was inserted ≤ 6 months (i.e., within 180 days) of consent, and willing to comply to the LUX-Dx Latitude Clarity transmission instructions

Exclusion Criteria

1. Any of the following atrial conditions:

1. Left atrial anteroposterior diameter ≥ 5.5 cm, or if1 LA diameter not available, non-indexed volume \>100 ml (physician note or imaging)
2. Any prior left atrial ablation
3. Any prior atrial surgery
4. Current atrial myxoma
5. Current left atrial thrombus
6. Any PV abnormality, stenosis, or stenting (common and middle PVs are admissible)
2. Any of the following cardiovascular conditions:

1. History of sustained ventricular tachycardia or any ventricular fibrillation
2. Severe right ventricular dysfunction with documented echocardiography and/or hemodynamic data, per Investigator's discretion
3. AF that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible / non-cardiac causes
4. Cardiac devices and implants:

* Current or anticipated pacemaker, implantable cardioverter defibrillator or cardiac resynchronization therapy devices
* Implantable loop recorder, other than LUX-Dx
* Interatrial baffle, patent foramen ovale or atrial septal defect closure device or patch
* Any left atrial appendage closure or occlusion device
5. Presence of any of the following valvular conditions:

* Any prosthetic heart valve, stenotic valves, ring or repair
* Moderate to severe mitral valve stenosis
* More than moderate mitral regurgitation
6. Hypertrophic or amyloid cardiomyopathy
7. Any IVC filter, known inability to obtain vascular access or other contraindication to femoral access
8. Awaiting cardiac transplantation or other planned cardiac surgery within the next 12 months
9. Severe right ventricular dysfunction with documented echocardiography and/or hemodynamic data.
3. Any of the following conditions at Baseline:

1. Heart failure associated with NYHA Class III or IV
2. Most recent documented LVEF \< 40% within the previous 12 months
3. Body Mass Index (BMI) \> 45.0
4. Known coagulopathy or bleeding disorder
5. Contraindication to, or unwillingness to use systemic anticoagulation, or acceptable alternatives, pre-, intra- and post-procedure to achieve adequate anticoagulation
6. Women who are confirmed to be pregnant or lactating at the time of the ablation procedure
7. Severe lung disease, severe pulmonary hypertension, or any lung disease involving abnormal blood gases or requiring supplemental oxygen
8. Active malignancy (other than squamous cell carcinoma)
9. Clinically significant gastrointestinal problems involving the esophagus or stomach including severe or erosive esophagitis, uncontrolled gastric reflux, gastroparesis, esophageal candidiasis or active gastroduodenal ulceration
10. Known active systemic infection
11. Untreated diagnosed obstructive sleep apnea with apnea hypopnea index classification of severe (\>30 pauses per hour) as per the guidelines
12. Predicted life expectancy less than one year per investigator medical judgement
13. Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments; each instance must be brought to the attention of the Sponsor to determine eligibility
14. Required use of phosphodiesterase inhibitors within 24 hours of the ablation procedure
15. Uncontrolled hypertension (SBP \> 160 mmHg or DBP \> 95 mmHg on two (2) BP measurements at baseline assessment not attributable to white coat syndrome per Investigator opinion
16. CHA2DS2-VASc score ≥ 5
17. Known allergic drug reaction to nitroglycerin (excluding hypotension)
18. Unwillingness to receive, or unable to tolerate, a subcutaneous, chronically inserted LUX-Dx ICM device
4. Any of the following congenital conditions:

1. Congenital heart disease with any clinically significant residual anatomic or conduction abnormality
2. History of known congenital methemoglobinemia
3. History of known G6PD deficiency
5. Any of the following conditions in the medical history:

1. Solid organ or hematologic transplant, or currently being evaluated for a transplant
2. Any prior history or current evidence of hemi-diaphragmatic paralysis or paresis
3. Any documented history of Prinzmetal Angina or severe non-revascularizable coronary disease
4. Renal insufficiency if an estimated glomerular filtration rate (eGFR) is \< 30 mL / min / 1.73 m2, or with any history of renal dialysis or renal transplant
5. Any other general health condition that, in the investigator's medical opinion, would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation.
6. Any of the following events less than or equal to 90 days of the consent date:

1. Myocardial infarction (MI), unstable angina or coronary intervention
2. Any cardiac surgery
3. Heart failure hospitalization
4. Pericarditis or symptomatic pericardial effusion
5. Gastrointestinal bleeding
6. Stroke, TIA, or intracranial bleeding
7. Any active non-neurologic thrombus and/or thromboembolic event
8. Carotid stenting or endarterectomy
9. Uncontrolled diabetes mellitus or a recorded HbA1c \> 8.0%

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.